Afiveg / Mynzepli
Aflibercept biosimilar developed by Alvotech, development code AVT06. Reference product Eylea.
Brands by market: Afiveg (EU, Stada); Mynzepli (EU, Advanz) · Commercial partner or holder: Stada (EU); Advanz Pharma (EU)
FDAnot listed
EMAAug 2025authorised
CDSCOnot listed
EDEnot listed
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union · Afiveg
European Medicines Agency and European CommissionApprovedBrand
Afiveg
Holder or applicant
STADA Arzneimittel AG
Pathway
Centralised (Article 10(4))
Approved
Aug 2025
Application or permission
EMEA/H/C/006761
Presentations
see SmPC
Source
S017
EMA
European Union · Mynzepli
European Medicines Agency and European CommissionApprovedBrand
Mynzepli
Holder or applicant
Advanz Pharma Limited
Pathway
Centralised (Article 10(4))
Approved
Aug 2025
Application or permission
EMEA/H/C/006438
Presentations
see SmPC
Source
S017
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Chronology
- EMAAug 2025Authorised by the European Commission as Afiveg
- EMAAug 2025Authorised by the European Commission as Mynzepli
Sources
S017EMA, medicines data table (medicines-output-medicines-report_en.xlsx) Primary (regulator)
Planning aflibercept biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.